Skip to main content Accessibility help
×
Home

Management of impulse control disorders in Parkinson's disease

  • Susan Zhang (a1) (a2), Nadeeka N. Dissanayaka (a1) (a3) (a4), Andrew Dawson (a5), John D. O'Sullivan (a3) (a2), Philip Mosley (a2) (a6) (a7), Wayne Hall (a8) and Adrian Carter (a1) (a5)...

Abstract

Background:

Impulse control disorders (ICDs) have become a widely recognized non-motor complication of Parkinson's disease (PD) in patients taking dopamine replacement therapy (DRT). There are no current evidence-based recommendations for their treatment, other than reducing their dopaminergic medication.

Methods:

This study reviews the current literature of the treatment of ICDs including pharmacological treatments, deep brain stimulation, and psychotherapeutic interventions.

Results:

Dopamine agonist withdrawal is the most common and effective treatment, but may lead to an aversive withdrawal syndrome or motor symptom degeneration in some individuals. There is insufficient evidence for all other pharmacological treatments in treating ICDs in PD, including amantadine, serotonin selective reuptake inhibitors, antipsychotics, anticonvulsants, and opioid antagonists (e.g. naltrexone). Large randomized control trials need to be performed before these drugs can be routinely used for the treatment of ICDs in PD. Deep brain stimulation remains equivocal because ICD symptoms resolve in some patients after surgery but may appear de novo in others. Cognitive behavioral therapy has been shown to improve ICD symptoms in the only published study, although further research is urgently needed.

Conclusions:

Further research will allow for the development of evidence-based guidelines for the management of ICDs in PD.

Copyright

Corresponding author

Correspondence should be addressed to: Adrian Carter, Senior Research Fellow, Brain & Mental Health Laboratory, School of Psychological Sciences, Monash University, 770 Blackburn Rd, Monash University, Clayton VIC 3800, Australia. Phone: +61 3 9902 9431. Email: adrian.carter@monash.edu.

References

Hide All
Amami, P. et al. (2014). Impulse control behaviours in patients with Parkinson's disease after subthalamic deep brain stimulation: de novo cases and 3-year follow-up. Journal of Neurology, Neurosurgery & Psychiatry, 86, 562564.
American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Washington, DC: American Psychiatric Publishing.
Armon, C. et al. (1996). Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology, 47, 626635.
Ardouin, C. et al. (2006). Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Movement Disorders : Official Journal of the Movement Disorder Society, 21, 19411946.
Ardouin, C. et al. (2009). Assessment of hyper- and hypodopaminergic behaviors in Parkinson's disease. Revue Neurologique, 165, 845856.
Barone, P. et al. (2010). Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. The Lancet Neurology, 9, 573580.
Bermejo, P. E. (2008). Topiramate in managing impulse control disorders in Parkinson's disease. Parkinsonism and Related Disorders, 14, 448449.
Bermejo, P. E., Ruiz-Huete, C. and Anciones, B. (2010). Zonisamide in managing impulse control disorders in Parkinson's disease. Journal of Neurology, 257, 16821685.
Bortolato, M., Cannas, A., Solla, P., Bini, V., Puligheddu, M. and Marrosu, F. (2012). Finasteride attenuates pathological gambling in patients with Parkinson disease. Journal of Clinical Psychopharmacology, 32, 424425.
Broen, M., Duits, A., Visser-Vandewalle, V., Temel, Y. and Winogrodzka, A. (2011). Impulse control and related disorders in Parkinson's disease patients treated with bilateral subthalamic nucleus stimulation: a review. Parkinsonism and Related Disorders, 17, 413417.
Callesen, M. B., Scheel-Kruger, J., Kringelbach, M. L. and Moller, A. (2013). A systematic review of impulse control disorders in Parkinson's disease. Journal of Parkinson's Disease, 3, 105138.
Cavanagh, J. F. et al. (2011). Subthalamic nucleus stimulation reverses mediofrontal influence over decision threshold. Nature Neuroscience, 14, 14621467.
Connolly, B. S. and Fox, S. H. (2012). Drug treatments for the neuropsychiatric complications of Parkinson's disease. Expert Review of Neurotherapeutics, 12, 14391449.
Crosby, N. J., Deane, K. H. and Clarke, C. E. (2003). Amantadine for dyskinesia in Parkinson's disease. Cochrane Database of Systematic Reviews, 2, CD003467.
Dagher, A. and Robbins, T. W. (2009). Personality, addiction, dopamine: insights from Parkinson's disease. Neuron, 61, 502510.
Delaney, M., Leroi, I., Simpson, J. and Overton, P. G. (2012). Impulse control disorders in Parkinson's disease: a psychosocial perspective. Journal of Clinical Psychology in Medical Settings, 19, 338346.
Dodd, M. L., Klos, K. J., Bower, J. H., Geda, Y. E., Josephs, K. A. and Ahlskog, J. E. (2005). Pathological gambling caused by drugs used to treat Parkinson disease. Archives of Neurology, 62, 13771381.
Doll, B. B. and Frank, M. J. (2009). Chapter 19 - The basal ganglia in reward and decision making: computational models and empirical studies. In Dreher, J.-C. and Tremblay, L. (eds.), Handbook of Reward and Decision Making (pp. 399425). New York: Academic Press.
Eusebio, A. et al. (2013). Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry, 84, 868874.
Evans, A. H. et al. (2004). Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Movement Disorders: Official Journal of the Movement Disorder Society, 19, 397405.
Fernandez, H. H. and Durso, R. (1998). Clozapine for dopaminergic-induced paraphilias in Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 13, 597598.
Frank, M. J., Samanta, J., Moustafa, A. A. and Sherman, S. J. (2007). Hold your horses: impulsivity, deep brain stimulation, and medication in Parkinsonism. Science, 318, 13091312.
Gee, L. et al. (2015). The influence of bilateral subthalamic nucleus deep brain stimulation on impulsivity and prepulse inhibition in Parkinson's disease patients. Stereotactic and Functional Neurosurgery, 93, 265270.
Gerlach, M., Double, K., Arzberger, T., Leblhuber, F., Tatschner, T. and Riederer, P. (2003). Dopamine receptor agonists in current clinical use: comparative receptor binding profiles defined in the human striatum. Journal of Neural Transmission, 110, 11191127.
Grant, J. E., Kim, S. W. and Odlaug, B. L. (2007). N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biological Psychiatry, 62, 652657.
Grant, J. E., Odlaug, B. L., Potenza, M. N., Hollander, E. and Kim, S. W. (2010). Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study. The British Journal of Psychiatry: The Journal of Mental Science, 197, 330331.
Green, N., Bogacz, R., Huebl, J., Beyer, A. K., Kuhn, A. A. and Heekeren, H. R. (2013). Reduction of influence of task difficulty on perceptual decision making by STN deep brain stimulation. Current Biology, 23, 16811684.
Gurevich, E. V. and Joyce, J. N. (1999). Distribution of dopamine D3 receptor expressing neurons in the human forebrain: Comparison with D2 receptor expressing neurons. Neuropsychopharmacology, 20, 6080.
Halbig, T. D. et al. (2009). Subthalamic deep brain stimulation and impulse control in Parkinson's disease. European Journal of Neurology, 16, 493497.
Hardwick, A., Ward, H., Hassan, A., Romrell, J. and Okun, M. S. (2013). Clozapine as a potential treatment for refractory impulsive, compulsive, and punding behaviors in Parkinson's disease. Neurocase, 19, 587591.
Haynes, W. I. and Haber, S. N. (2013). The organization of prefrontal-subthalamic inputs in primates provides an anatomical substrate for both functional specificity and integration: implications for Basal Ganglia models and deep brain stimulation. Journal of Neuroscience, 33, 48044814.
Hershey, T., Revilla, F. J., Wernle, A., Gibson, P. S., Dowling, J. L. and Perlmutter, J. S. (2004). Stimulation of STN impairs aspects of cognitive control in PD. Neurology, 62, 11101114.
Hicks, C. W., Pandya, M. M., Itin, I. and Fernandez, H. H. (2011). Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease. Parkinsonism & Related Disorders, 17, 379381.
Hollander, E., DeCaria, C. M., Finkell, J. N., Begaz, T., Wong, C. M. and Cartwright, C. (2000). A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biological Psychiatry, 47, 813817.
Ivanco, L. S. and Bohnen, N. I. (2005). Effects of donepezil on compulsive hypersexual behavior in Parkinson disease: a single case study. American Journal of Therapeutics, 12, 467468.
Kehagia, A. A. et al. (2014). Targeting impulsivity in Parkinson's disease using atomoxetine. Brain, 137, 19861997.
Kurlan, R. (2004). Disabling repetitive behaviors in Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 19, 433437.
Lambert, C. et al. (2012). Confirmation of functional zones within the human subthalamic nucleus: patterns of connectivity and sub-parcellation using diffusion weighted imaging. Neuroimage, 60, 8394.
Lee, J. Y., Kim, H. J. and Jeon, B. S. (2011). Is pathological gambling in Parkinson's disease reduced by amantadine? Annals of Neurology, 69, 213214; author reply 214–215.
Lhommee, E. et al. (2012). Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours. Brain, 135, 14631477.
Liang, J. W., Shanker, V. L. and Groves, M. (2015). Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology, 84, 13861387.
Lim, S. Y., Evans, A. H. and Miyasaki, J. M. (2008). Impulse control and related disorders in Parkinson's disease: review. Annals of the New York Academy of Sciences, 1142, 85107.
Lim, S. Y. et al. (2009). Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. Journal of Clinical Neuroscience, 16, 11481152.
Lu, C., Bharmal, A. and Suchowersky, O. (2006). Gambling and Parkinson disease. Archives of Neurology, 63, 298.
Macphee, G. J., Chaudhuri, K. R., David, A. S., Worth, P. and Wood, B. (2013). Managing impulse control behaviours in Parkinson's disease: practical guidelines. British Journal of Hospital Medicine, 74, 160166.
Macphee, G. J., Copeland, C., Stewart, D., Grosset, K. and Grosset, D. G. (2009). Clinical follow up of pathological gambling in Parkinson's disease in the West Scotland study. Movement Disorders : Official Journal of the Movement Disorder Society, 24, 24302431.
Mamikonyan, E. et al. (2008). Long-term follow-up of impulse control disorders in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society, 23, 7580.
McElroy, S. L., Keck, P. E. Jr., Pope, H. G. Jr., Smith, J. M. and Strakowski, S. M. (1994). Compulsive buying: a report of 20 cases. Journal of Clinical Psychiatry, 55, 242248.
Mestre, T. A., Strafella, A. P., Thomsen, T., Voon, V. and Miyasaki, J. (2013). Diagnosis and treatment of impulse control disorders in patients with movement disorders. Therapeutic Advances in Neurological Disorders, 6, 175188.
Moum, S. J. et al. (2012). Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. PLoS One, 7, e29768.
Nirenberg, M. (2013). Dopamine agonist withdrawal syndrome: implications for patient care. Drugs & Aging, 30, 587592.
Nirenberg, M. J. and Waters, C. (2006). Compulsive eating and weight gain related to dopamine agonist use. Movement Disorders : Official Journal of the Movement Disorder Society, 21, 524529.
Obeso, I. et al. (2011). Deficits in inhibitory control and conflict resolution on cognitive and motor tasks in Parkinson's disease. Experimental Brain Research, 212, 371384.
Okai, D., Askey-Jones, S., Samuel, M., David, A. S. and Brown, R. G. (2015). Predictors of response to a cognitive behavioral intervention for impulse control behaviors in Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 30, 736739.
Okai, D. et al. (2013). Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology, 80, 792799.
Papay, K. et al. (2014). Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology, 83, 826833.
Parkinson Study Group. (1997). Safety and efficacy of pramipexole in early Parkinson disease. JAMA, 278, 125130.
Rabinak, C. A. and Nirenberg, M. J. (2010). Dopamine agonist withdrawal syndrome in Parkinson disease. Archives of Neurology, 67, 5863.
Rotondo, A., Bosco, D., Plastino, M., Consoli, A. and Bosco, F. (2010). Clozapine for medication-related pathological gambling in Parkinson disease. Movement Disorders : Official Journal of the Movement Disorder Society, 25, 19941995.
Ruggieri, S., De, P. M. F., Bonamartini, A., Vacca, L. and Stocchi, F. (1997). Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson's disease. Clinical Neuropharmacology, 20, 204209.
Schneider, C., Corrigall, R., Hayes, D., Kyriakopoulos, M. and Frangou, S. (2013). Systematic review of the efficacy and tolerability of Clozapine in the treatment of youth with early onset schizophrenia. European Psychiatry: The Journal of the Association of European Psychiatrists, 29, 110.
Schreiber, L., Odlaug, B. L. and Grant, J. E. (2011). Impulse control disorders: updated review of clinical characteristics and pharmacological management. Front Psychiatry, 2, 1.
Schuepbach, W. M. et al. (2013). Neurostimulation for Parkinson's disease with early motor complications. New England Journal of Medicine, 368, 610622.
Seppi, K. et al. (2011). The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 26 (Suppl. 3), S42S80.
Sevincok, L., Akoglu, A. and Akyol, A. (2007). Quetiapine in a case with Parkinson disease and pathological gambling. Journal of Clinical Psychopharmacology, 27, 107108.
Shotbolt, P. et al. (2012). Relationships between deep brain stimulation and impulse control disorders in Parkinson's disease, with a literature review. Parkinsonism & Related Disorders, 18, 1016.
Silberstein, P. et al. (2009). Deep brain stimulation for Parkinson's disease: Australian referral guidelines. Journal of Clinical Neuroscience, 16, 10011008.
Smeding, H. M., Goudriaan, A. E., Foncke, E. M., Schuurman, P. R., Speelman, J. D. and Schmand, B. (2007). Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease. Journal of Neurology Neurosurgery & Psychiatry, 78, 517519.
Sokoloff, P., Giros, B., Martes, M. P., Bouthenet, M. L. and Schwartz, J. C. (1990). Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature, 347, 146151.
Sohtaoglu, M., Demiray, D. Y., Kenangil, G., Ozekmekci, S. and Erginoz, E. (2010). Long term follow-up of Parkinson's disease patients with impulse control disorders. Parkinsonism & Related Disorders, 16, 334337.
Thibaut, F., De, L. B. F., Gordon, H., Cosyns, P. and Bradford, J. M. (2010). The world federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of paraphilias. The World Journal of Biological Psychiatry: The Official Journal of the World Federation of Societies of Biological Psychiatry, 11, 604655.
Thobois, S. et al. (2007). STN stimulation alters pallidal-frontal coupling during response selection under competition. Journal of Cerebral Blood Flow and Metabolism, 27, 11731184.
Thobois, S. et al. (2010). Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain: A Journal of Neurology, 133, 11111127.
Thomas, A., Bonanni, L., Gambi, F., Di Iorio, A. and Onofrj, M. (2010). Pathological gambling in Parkinson disease is reduced by amantadine. Annals of Neurology, 68, 400404.
Trosch, R. M. et al. (1998). Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience. Movement Disorders: Official Journal of the Movement Disorder Society, 13, 377382.
Voon, V. et al. (2006). Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology, 67, 12541257.
Voon, V. et al. (2007). Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Archives of Neurology, 64, 212216.
Voon, V. et al. (2011). Impulse control disorders in Parkinson disease: a multicenter case control study. Annals of Neurology, 69, 986996.
Walsh, R. A. and Lang, A. E. (2012). Multiple impulse control disorders developing in Parkinson's disease after initiation of amantadine. Movement Disorders: Official Journal of the Movement Disorder Society, 27, 326.
Weintraub, D. (2008). Dopamine and impulse control disorders in Parkinson's disease. Annals of Neurology, 64 (Suppl. 2), S93S100.
Weintraub, D. et al. (2006). Association of dopamine agonist use with impulse control disorders in Parkinson disease. Archives of Neurology, 63, 969973.
Weintraub, D. et al. (2010a). Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Archives of Neurology, 67, 589595.
Weintraub, D. et al. (2010b). Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Annals of Neurology, 68, 963968.
Witt, K. et al. (2004). Deep brain stimulation of the subthalamic nucleus improves cognitive flexibility but impairs response inhibition in Parkinson disease. Archives of Neurology, 61, 697700.

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed